Navigation Links
Novo Nordisk Addresses Innovation in Diabetes Care in Second Issue of Industry Resource for Information on Diabetes and Chronic Disease
Date:7/12/2010

PRINCETON, N.J., July 12 /PRNewswire/ -- Novo Nordisk Inc., a global healthcare company and leader in diabetes care, today announced the second issue of the Novo Nordisk BlueSheet, a resource for information on diabetes and chronic disease, highlighting key issues in diabetes prevention, detection, treatment and care.

The second issue of the Novo Nordisk BlueSheet examines how insulin has evolved over the last 90 years, how it is developed today, the use of insulin devices in the U.S., and the outlook for next generation insulins. Each quarter, the Novo Nordisk BlueSheet will highlight key issues in diabetes prevention, detection, treatment and care, as well as related topics from the legislative process to public education.

To read the Novo Nordisk BlueSheet, go to: http://press.novonordisk-us.com/bluesheet.

"Innovation and scientific research and discovery are our most powerful tools in defeating diabetes with better methods of disease prevention, detection, treatment, and care," said Jerzy Gruhn, president of Novo Nordisk Inc. "At Novo Nordisk, we are committed to building an environment that supports the discovery of new products and solutions that can significantly impact the millions of people living with diabetes."

About Novo Nordisk

Novo Nordisk is a global healthcare company with more than 87 years of innovation and leadership in diabetes care.  The company also has leading positions within hemophilia care, growth hormone therapy and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to social responsibility to employees and customers, environmental soundness and economic success.  Headquartered in Denmark, Novo Nordisk employs more than 29,300 employees in 76 countries, and markets its products in 179 countries.  Novo Nordisk's B shares are listed on the stock exchange in Copenhagen and its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk-us.com.


'/>"/>
SOURCE Novo Nordisk Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Novo Nordisk Announces Resources to Help Support Kids with Diabetes Attending Summer Camp
2. Novo Nordisk Awards More Than $300,000 in Grants to Support Education and Community Health Programs
3. Novo Nordisk partners with international scientific community for Victoza(R) cardiovascular outcomes trial
4. Novo Nordisk Awarded Department of Veterans Affairs National Insulin Contract
5. Novo Nordisks Victoza(R) Receives FDA Approval for Adults With Type 2 Diabetes
6. Novo Nordisk is Changing Possibilities in Hemophilia
7. Novo Nordisk Wins Design Award for NovoTwist(TM) Needle
8. Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes
9. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
10. Dr. Joan Fallon, Curemark CEO, Addresses Keystone Symposia Meeting On Autism
11. Baxa Addresses Health-System Capital Shortage With New Programs for IntelliFlowRx(TM) and IntelliFill i.v.(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... Mass. , Oct. 4, 2017 ... of single-use, self-contained, illuminating medical devices, today announced ... National Health Surveillance Agency (or Agência Nacional de ... The first single-use, cordless surgical retractor with integrated ... provides optimal access, illumination and exposure of a ...
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, ... formed by Walgreens and pharmacy benefit manager Prime Therapeutics ... new brand, which included the unveiling of new signage ... , as well as at a few other company-owned ... new brand to patients, some of whom will begin ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, ... 2017 earnings conference call and webcast on Friday, November ... a.m. (EDT) and ending at approximately 8:30 a.m. (CDT) ... discussing the company,s 2017 financial performance and guidance for ... opportunities, initiatives to enhance operational performance, and long-range financial ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... ... 2017 , ... HMP , a leader in healthcare events and education, today ... Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & ... award competition recognizes editorial and design excellence across a range of sectors. This year’s ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health & ... by Moonlight to raise money for the American Heart Association Heart Walk. Teams of ... will work together to keep their treadmills moving for 5 hours. Treadmills will start ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health ... interactive health literacy software tool, and the Cancer Patient Education Network (CPEN), an ... education, today announce a new strategic alliance. , As CPEN’s strategic partner, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra Chief Medical ... to physician colleagues, skilled nursing facility medical directors and other clinicians at various ... Wound Care." , "At many of these conferences we get to educate other ...
Breaking Medicine News(10 mins):